GGrantIndex
← Leaderboards

Anand Viswanathan

Massachusetts General Hospital

$12,542,460
Attributed
$12,542,460
Total exposure
4
Grants
4
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $1.5M · FY200925
$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$12,542,460 · 4

By mechanism

R01$10,949,304 · 2
K23$822,825 · 1
P50$770,331 · 1

Top collaborators

No co-investigators on record.

Most similar at Massachusetts General Hospital

Same institution · by research overlap

Others in their field

Top investigators on “Alzheimer&Apos

Research focus

Alzheimer&AposCerebral Amyloid AngiopathyCerebrumLesionMagnetic Resonance ImagingImpaired CognitionBlood VesselsPathologyDementiaDepositionWhite MatterImageS DiseaseFutureAmyloidBaseTau ProteinsFundingArteriesBiological MarkersAge RelatedBrainCohortDiagnosis

Grant awards (25)

Vascular Pathology in Early and Asymptomatic Cerebral Amyloid Angiopathy$785,505
R01 · FY2025 · AG · contact PI
Vascular Pathology in Early and Asymptomatic Cerebral Amyloid Angiopathy$801,535
R01 · FY2024 · AG · contact PI
Vascular Pathology in Early and Asymptomatic Cerebral Amyloid Angiopathy$801,535
R01 · FY2023 · AG · contact PI
Vascular Pathology in Early and Asymptomatic Cerebral Amyloid Angiopathy$801,535
R01 · FY2022 · AG · contact PI
Validation of Small-Vessel Disease Neuroimaging Biomarkers in Cerebral Amyloid Angiopathy-Related Cognitive Decline$681,122
R01 · FY2022 · NS · contact PI
Vascular Pathology in Early and Asymptomatic Cerebral Amyloid Angiopathy$803,215
R01 · FY2021 · AG · contact PI
Validation of Small-Vessel Disease Neuroimaging Biomarkers in Cerebral Amyloid Angiopathy-Related Cognitive Decline$681,122
R01 · FY2021 · NS · contact PI
Validation of Small-Vessel Disease Neuroimaging Biomarkers in Cerebral Amyloid Angiopathy-Related Cognitive Decline$681,122
R01 · FY2020 · NS · contact PI
Validation of Small-Vessel Disease Neuroimaging Biomarkers in Cerebral Amyloid Angiopathy-Related Cognitive Decline$691,003
R01 · FY2019 · NS · contact PI
Vascular Pathology in Early and Asymptomatic Cerebral Amyloid Angiopathy$708,659
R01 · FY2018 · AG · contact PI
Validation of Small-Vessel Disease Neuroimaging Biomarkers in Cerebral Amyloid Angiopathy-Related Cognitive Decline$696,009
R01 · FY2018 · NS · contact PI
Vascular Pathology in Early and Asymptomatic Cerebral Amyloid Angiopathy$708,659
R01 · FY2017 · AG · contact PI
Vascular Pathology in Early and Asymptomatic Cerebral Amyloid Angiopathy$708,659
R01 · FY2016 · AG · contact PI
Vascular Pathology in Early and Asymptomatic Cerebral Amyloid Angiopathy$687,398
R01 · FY2015 · AG · contact PI
Vascular Pathology in Early and Asymptomatic Cerebral Amyloid Angiopathy$712,226
R01 · FY2014 · AG · contact PI
Effect of White Matter Disease on Gait and Balance in Cerebral Amyloid Angiopathy$164,565
K23 · FY2014 · AG · contact PI
Effect of White Matter Disease on Gait and Balance in Cerebral Amyloid Angiopathy$164,565
K23 · FY2013 · AG · contact PI
THE ROLE OF ADVANCED CAA IN ALZHEIMER'S DEMENTIA$143,893
P50 · FY2013 · AG · contact PI
THE ROLE OF ADVANCED CAA IN ALZHEIMER'S DEMENTIA$165,388
P50 · FY2012 · AG · contact PI
Effect of White Matter Disease on Gait and Balance in Cerebral Amyloid Angiopathy$164,565
K23 · FY2012 · AG · contact PI
Effect of White Matter Disease on Gait and Balance in Cerebral Amyloid Angiopathy$164,565
K23 · FY2011 · AG · contact PI
THE ROLE OF ADVANCED CAA IN ALZHEIMER'S DEMENTIA$153,848
P50 · FY2011 · AG · contact PI
Effect of White Matter Disease on Gait and Balance in Cerebral Amyloid Angiopathy$164,565
K23 · FY2010 · AG · contact PI
THE ROLE OF ADVANCED CAA IN ALZHEIMER'S DEMENTIA$155,402
P50 · FY2010 · AG · contact PI
THE ROLE OF ADVANCED CAA IN ALZHEIMER'S DEMENTIA$151,800
P50 · FY2009 · AG · contact PI